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Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden  
ABSTRACT 
Background: There are about 6600 patients diagnosed with colorectal cancer in 
Sweden each year. Survival rates vary with cancer stage at diagnosis. The main 
treatment is surgery together with, in some cases, oncological treatment. Matrix 
metalloproteinases (MMP) are deeply involved in the growth and spread of 
colorectal cancer tumours. The aim of this thesis was to validate the 
methodology of sample storing and the measurement of MMP concentrations 
and evaluating the prognostic value of MMP in colorectal cancer survival. 
Furthermore, an experimental model for studying human peritoneal surface, ex 
vivo, was validated. Methods: Study I – Blood samples were obtained from 65 
patients and analysed for MMP in citrated plasma and serum. Study II – Plasma, 
tumour biopsies and healthy intestinal biopsies were investigated before and 
after long-term cryopreservation to assess MMP level stability. In Study III a 
cohort of 272 patients were followed for 10 years after colorectal cancer surgery 
and the association between cancer-specific survival and plasma MMP 
concentration was analysed. Study IV - An ex vivo model of human peritoneum 
as well as a model for cultured mesothelial cells were developed. The models 
were subjected to trauma before introduction of cancer cells and followed by 
microscopy. Results: MMP have higher concentrations in serum compared to 
plasma and the variation in concentration is greater in serum samples. MMP 
concentration in plasma remains at the same level even after a long time in 
cryopreservation, while tissue extract concentrations appear to increase during 
storage. A high plasma concentration of MMP-1 in patients with non-
disseminated disease was linked to worse cancer-specific survival after 
colorectal cancer surgery. The mesothelial cell model as well as the peritoneal 
model remained viable for long periods of time, and introduced cancer cells 
seemed to adhere to the edges of the traumatised area. Conclusion: Plasma 
samples are superior to serum samples when measuring MMP concentrations in 
circulating blood. Plasma samples could be stored for a long time at -80°C 
without MMP degradation. MMP-1 concentration in plasma in patients treated 
for colorectal cancer could have a prognostic value regarding cancer survival. 
Peritoneal models may be used to study colorectal cancer cell invasion and 
spread. 
Keywords: Colorectal neoplasms; matrix metalloproteinases; colorectal surgery; 
survival; prognosis; peritoneum; peritoneal neoplasms. 
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 Sammanfattning på svenska 
Bakgrund 
Tjock- och ändtarmscancer är den fjärde, respektive nionde, vanligaste 
cancerformen i Sverige och står tillsammans för ca 6 600 nya fall varje år. Den 
botande behandlingen är kirurgi där tumören opereras bort. I vissa fall används 
onkologisk behandling i form av cellgifter och/eller strålning som tillägg till 
kirurgi. Endast cirka 15 % av patienter som erhåller tilläggsbehandling i form av 
cellgifter har effekt av behandlingen. Överlevnaden i tjock och ändtarmscancer 
har förbättrats de senaste decennierna, patienter som drabbas har en beräknad 5-
årsöverlevnad på ca 65 %. Överlevnaden varierar dock i stor grad, beroende på 
hur tumören har vuxit och om det finns dottertumörer i övriga organ i kroppen. 
Matrix metalloproteinaser (MMP) är en grupp kroppsegna enzym som kan bryta 
ned beståndsdelar i det extracellulära rummet samt bidra till kärltillväxt och 
spridning av tjock- och ändtarmstumörer. Det har tidigare visats att det finns en 
korrelation av höga nivåer av MMPs i och kring tumören och överlevnad i 
cancersjukdom. Studier har också indikerat att höga nivåer av MMPs i 
blodplasma och serum kan ha koppling till cancerspecifik överlevnad hos 
patienter med tjock- och ändtarmscancer. 
Spridning till bukhinnan är en fruktad följd av avancerad tjock- och 
ändtarmscancer. Biologin kring tumörinvasion och spridning på bukhinnan är 
inte helt känd och en anledning kan vara att det hittills saknats experimentella 
modeller för att studera detta förlopp.  
Målsättning 
Syftet med denna avhandling har varit att validera metoderna för mätning och 
förvaring av biologiska prov avseende olika typer av MMPs. Vidare har 
målsättningen varit att undersöka huruvida vissa MMPs, mätt i cirkulerande blod 
kan vara av prognostisk betydelse för överlevnad i tjock- och ändtarmscancer. 
Ytterligare ett mål har varit att validera en experimentell modell för att kunna 
studera mänsklig bukhinnevävnad i laboratoriemiljö för att få bättre förståelse 
om tumörbiologin vid spridning till bukhinnan. 
  
Metod och resultat 
I Delarbete I jämfördes nivåer av MMPs i blodplasma respektive serum hos 65 
patienter. Vid analysen observerades att MMP-nivåer mätta i serumprover hade 
en större variation och bedömdes vara mer osäkra jämfört med plasmaprover. 
Delarbete II fokuserade på lagring av blod och vävnadsprover. Koncentration av 
MMPs mättes i plasmaprover, i tumörvävnad och tarmvävnad utan tumörväxt. 
Efter nio respektive 12 år gjordes nya mätningar på samma prover vilka visade 
att plasmaproverna var stabila och MMP-koncentrationen inte hade ändrat sig 
under lagringstiden. MMP-koncentrationerna ökade däremot under lagringstiden 
i såväl tumör- som tarmvävnad. Plasmanivåer och dess relation till överlevnad 
vid tjock- och ändtarmssjukdom undersöktes i Delarbete III. Nivåer av MMP i 
blodplasma undersöktes hos 272 patienter som opererades för tjock- eller 
ändtarmscancer vid Sahlgrenska Universitetssjukhuset/Östra 1999-2004. 
Plasmanivåerna jämfördes sedan med överlevnadsdata. Patienter med ett högt 
värde av MMP-1 i plasma hade kortare cancerspecifik överlevnad. Slutsatsen 
drogs att MMP-1 mätt i blodplasma sannolikt har ett prognostiskt värde och kan 
vara värdefullt vid uppföljning och behandling av patienter som drabbats av 
tjock- eller ändtarmscancer. I Delarbete IV validerades två experimentella 
modeller. I den ena modellen används odlade celler från bukhinnan och dessa 
undersöktes avseende påverkan från ett artificiellt kirurgiskt trauma. Det odlade 
cellagret skadades på ett standardiserat sätt och cellerna kunde sedan 
monitoreras genom mikroskopi. När humana cancerceller tillsattes noterades att 
cancercellerna verkade ha en tendens att fästa vid det skadade området. 
Detsamma gällde den andra modellen där bukhinna togs från patienter som 
genomgick kirurgi. Bukhinnan kunde sedan hållas viabel och studerades 
avseende påverkan av kirurgiskt trauma och tillsatta cancerceller. Modellerna 
kan ha stor betydelse i framtida studier för att ytterligare förstå biologin vid 
spridning av cancerceller från tjock- och ändtarm till bukhinnan. 
Slutsatser 
• Nivåer av cirkulerande MMPs bör mätas i blodplasma. 
• Plasmanivåer av MMPs är stabila, efter långvarig förvaring. 
• MMP-nivåer i vävnadsprover ter sig ej vara stabila över tid. 
• Koncentrationen av MMP-1 i plasma hos patienter med tjock- 
eller ändtarmscancer kan ha ett prognostiskt värde avseende 
överlevnad. 
• Modellen för att studera odlade celler och hel bukhinna 
fungerar och kan vara av stort värde i kommande studier av 
avancerad tjock- och ändtarmscancer. 
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Introduction 
Colorectal Cancer 
Almost 3000 years ago, the natural course of a growing disease with intestinal 
origin was described as a treat to Joram, King of Judah by the prophet Elijah1.  
“And you yourself will have a severe sickness with a  
disease of your bowels, until your bowels come out  
because of the disease, day by day... The lord struck  
him in his bowels with an incurable disease. In the  
course of time, at the end of two years, his bowels  
came out because of the disease, and he died in  
great agony.” 
 
Since then, the science of medicine has evolved, several milestones have been 
reached and colorectal cancer is no longer incurable. Tumours of the colorectal 
tract were later described by the Greek physician Aulus Celsus (25 BC-AD 50)2. 
Thereafter it took almost 2000 years until the first report of colon cancer surgery 
in 1823. It remained a rather unusual procedure; only ten colon resections had 
been reported by 1880. By the late 19th century, numbers of segmental resection 
of the colon had increased and the mortality rate began to decline3. The first 
procedure with radical intent for rectal cancer was performed in 19074.  
Surgical techniques have changed dramatically over time. In 1908, the 
distribution of lymph nodes following the arterial blood supply of the colon was 
discovered, and the principal of resection of these vessels and lymph nodes was 
proposed as part of surgery for colon and rectal cancer5. Surgery for rectal 
cancer further evolved during the 20th century when several approaches to 
radical surgery were developed. A major advance was made by Dr R J Heald 
with the development of the total mesorectum excision (TEM) technique in the 
early 1980s6. Further progress in the treatment of colorectal cancer was made as 
a result of the introduction of adjuvant and neoadjuvant therapies. The use of 
preoperative radiotherapy in selected rectal cancer cases in the 1990s increased 
survival and decreased local recurrence rates even more7. Chemotherapy has also 
made great advances since its introduction in the middle of the 20th century. The 
first reported chemotherapy agent, 5-FU is still in use, but there are now 
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numerous new agents available, including targeting therapies with monoclonal 
antibodies8. 
Incidence and Survival 
Globally there are around 1.2 million new colorectal cancer (CRC) cases each 
year, predominantly in developed countries. However an 80 % increase in CRC 
cases is estimated over the coming two decades, mostly in developing countries9. 
Colorectal cancer is the fourth most common cause of death from cancer 
worldwide and the third most common form of cancer, accounting for 9.7 % of 
all cancer cases in the world10. In Sweden, about 6600 CRC cases are reported 
each year11. The median age at which colon cancer is diagnosed in Sweden is 
74.1 years. There is equal distribution between genders12. Rectal cancer, 
however, is more common in men with a ratio of 1.5:1, with a median age at 
diagnosis of 71 years13. The incidence of colon cancer has been increasing over 
the last 40 years while the incidence of rectal cancer has remained stable.  
Overall survival has improved over the last 20-30 years. This is due to improved 
surgical technique, including metastasis surgery of the liver, lungs and peritoneal 
surface, as well as use of new oncological treatments and enhanced staging 
procedures14-16.  
 
 
 
 
 
 
 
 
  
 
Andreas Jonsson 
3 
 
Figure 1a. Colon Cancer, 1980-2016. New cases per 100 000 
inhabitants. Age adjusted. Sweden. Cancerregistret, 
Socialstyrelsen. 
Figure 1b. Rectal Cancer, 1980-2016. New cases per 100 000 
inhabitants. Age adjusted. Sweden. Cancerregistret, 
Socialstyrelsen. 
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Figure 2a. Colon Cancer, 1980-2015.  
Relative survival. Sweden. Cancerregistret, 
Socialstyrelsen. 
Figure 2b. Rectal Cancer, 1980-2015.  
Relative survival. Sweden. Cancerregistret, 
Socialstyrelsen. 
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Epidemiology 
There are several known risk factors for developing colorectal cancer, such as 
obesity, smoking, alcohol and red meat. On the other hand there are reasons to 
believe that physical activity and diets high in starch decrease the risk for 
colorectal cancer. Inflammatory bowel disease has traditionally been thought to 
be a strong risk factor for the development of CRC. However, the risk is 
probably not as high as previously reported. Cumulative risk for CRC in patients 
with IBD is 1 %, 2 % and 5 % after 10, 20 and > 20 years disease duration 
respectively17-20. 
Approximately 5 % of all CRC patients have a specific inherited syndrome, the 
most common being the Lynch syndrome where   50 % - 80 % of individuals 
with this condition develop CRC during their lifetime. Individuals with an 
autosomal dominant mutation that leads to familial adenomatous polyposis 
(FAP), have a 100 % risk of developing CRC, whereas a less severe attenuated 
form of FAP has a 69 % lifetime risk for developing CRC21.  
Staging 
Colorectal tumour staging has a long history, with the Dukes classification first 
described in 1932. This classification ranges from Dukes A to Dukes D and is 
based on the anatomically characteristics of the tumour. This staging system was 
further refined to include the in-wall spread of tumour cells in 195422.  
The currently used TNM classification was developed by the American Joint 
Committee on Cancer (AJCC). As to date, the 7th edition is used and the 8th 
edition is on its way. Even the TNM system is based on the anatomical 
characteristics of the tumour, including tumour spread throughout the bowel 
wall, the spread to lymph nodes and the presence of metastatic disease23.  
In this thesis the 6th edition of The Union for International Cancer Control TNM 
classification system and staging (UICC stage) of cancer disease was used. 
Involvement of the tumour in the bowel wall is represented by the T stage: T1 
tumours have invaded the submucosa; T2 tumours have invaded the muscularis 
propria; T3 tumours have passed through the muscularis propria into the 
subserosa, or into the pericolic/perirectal tissue; and T4 tumours have invaded 
through the visceral peritoneum or into other organs. The N stage represents 
lymph node involvement: N0 indicates that there is no metastasis to regional 
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lymph nodes; if there are one to three lymph nodes with metastasis, the tumour 
is classified as N1; and if there are more than three lymph nodes involved it is 
classified as N2. The M stage represents distant metastasis where M0 implies no 
distant metastasis and M1 implies that distant metastasis are present24. The 
different TNM stages are visualised in Figure 3.  
UICC stages and corresponding 5-year cancer specific survival rates are shown 
in Table 125, 26.  
Figure 3.TNM stages of colorectal cancer. 
National Cancer Iinstitute. With permission    
Table 1. UICC stages and Cancer specific survival rates.
UICC Stage T stage N stage M stage 5-year CSS 
I T1 or T2 N0 M0 92.5 % 
IIa T3 N0 M0 83.6 % - 84.7 % 
IIb T4 N0 M0 69.1 % - 72.2 % 
IIIa T1 or T2 N1 M0 83.1 % - 83.4 % 
IIIb T3 or T4 N1 M0 64.1 % - 64.4 % 
IIIc Any T N2 M0 44.3 % - 44.8 % 
IV Any T Any N M1 8.1 % - 10.4 % 
Abbreviation:  UICC = Union for International Cancer control; CSS = Cancer Specific 
Survival. 
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Treatment 
Surgery 
Surgery is the cornerstone of colorectal cancer treatment. The principle of colon 
cancer surgery is a wide resection of the bowel to achieve a sufficient tumour-
free margin. To warrant that the lymphatic drainage is included in the specimen 
the embryological planes should be followed together with a standardized 
pattern of blood vessel resection27, 28.  
Location of the tumour is fundamental when deciding on the extent of surgical 
resection. A tumour in the ascending colon is treated with right-sided hemi-
colectomy where the ascending colon and mesocolon are resected, including 
proximal ligation of the corresponding blood vessels. A tumour in the proximal 
transverse colon is treated with an extended right-sided hemicolectomy. 
Tumours of the distal transverse colon as well as the descending colon are 
treated with left-sided hemicolectomy. Surgery is carried out in a similar fashion 
with resection of the corresponding mesocolon and vessels. However there is no 
consensus regarding exactly were the arterial blood supply should be ligated29-33. 
Rectal tumours are surgically removed according to the TME procedure where 
all the mesorectum, including the mesorectal fascia and the lymph nodes, 
draining the rectal tumour are resected. 
Neoadjuvant Therapy In Rectal Cancer 
For mid- and high-situated lymph node-negative T1- T3 rectal tumours, TME 
surgery is usually performed without any neoadjuvant treatment. However, more 
unfavourable rectal tumours with lymph node involvement, low-situated 
tumours, tumours that involve the mesorectal fascia, or tumours showing signs 
of extramural vascular invasion are treated with neoadjuvant radiation and/or 
chemotherapy to decrease the risk of local recurrence and/or to facilitate radical 
surgery6, 34-37. 
Neoadjuvant Therapy in Colon Cancer 
There are several on-going studies aimed to evaluate if neoadjuvant 
chemotherapy has a place in cases of more advanced colon cancer, i.e. high-risk 
Stages II and III38-40. Reliable clinical staging (cTNM) is fundamental in the 
decision to use neoadjuvant chemotherapy. Lymph node status is assessed using 
computed tomography. The accuracy of detecting pathological lymph nodes, i.e. 
Colorectal Cancer -  
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Stage III colon cancer, has been reported to have a sensitivity of 62 - 88 % and a 
specificity of 55 – 70 %41, 42. 
Adjuvant Therapy  
Adjuvant chemotherapy is given to selected patients depending on the TNM 
status. It is standard treatment for patients with Stage III disease, given they are 
fit enough to manage the systemic toxicity effects that follow this treatment43-45. 
In clinical practice colon cancer and rectal cancer are treated using the same 
adjuvant chemotherapy protocol, though the benefits of adjuvant chemotherapy 
in rectal cancer are not as well documented as in colon cancer. Despite updated 
TNM staging procedures and numerous attempts to find prognostic and 
predictive models, controversy still exists about how to treat patients with 
advanced Stage II CRC following surgery. There are no rigid indications, but 
selected Stage II patients with risk factors are normally recommended adjuvant 
chemotherapy46.  
Some Suggested Prognostic Markers 
Several attempts have been made to achieve a better prognostic model for the 
outcome of CRC patients. The TNM system is now in its 7th edition, but there is 
still concern about its reliability in predicting prognosis47-49. Furthermore, the 
TNM system is based on the anatomic and pathological findings in the specimen 
resected in the operating theatre, making the classification system not useful in 
the preoperative work up of the patient23. The TNM system includes the 
metastatic involvement of regional lymph nodes. Traditionally 12 harvested 
lymph nodes have been recommended to enable staging and exclude metastatic 
disease, though a greater yield of cancer-free lymph nodes may increase the 
chance of survival50. 
There are many reasons to refine prognostic models for patients with CRC, 
including individualisation of treatment and follow-up programmes.  
CEA 
Circulating biomarkers of colorectal cancer have been extensively studied, but as 
yet only one biomarker has been widely used i.e. Carcinoembryonic Antigen 
(CEA). CEA is a normal product of the cell but is over-expressed in colon and 
rectum adenocarcinoma cells, as well as in other forms of adenocarcinoma51. 
CEA is mainly used as a monitoring biomarker following colorectal tumour 
resection, even though its sensitivity and specificity are questioned52-54. There 
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are studies, however, supporting the use of serum CEA levels as a diagnostic 
tool in CRC and colorectal adenomas55. Furthermore, CEA levels have been 
showed to increase with tumour stage and could be used to identify patients with 
a greater disease burden56. 
Circulating Tumour DNA 
Circulating tumour DNA (ctDNA) from CRC tumours may be found in serum 
and plasma. As with CEA, ctDNA levels increase in patients with colorectal 
cancer disease and fall significantly after CRC surgery. ctDNA levels correlate 
with tumour stage and increase with cancer recurrence so it could also  e used as 
a monitoring marker after CRC surgery57, 58. ctDNA is of most useful in more 
advanced stages of CRC as earlier stages does not express enough ctDNA to be 
measured in circulated blood59.  
Thymidylate synthase 
Thymidylate synthase (TS) is involved in the synthesis of dTTP which is 
essential for DNA synthesis. A high concentration of TS correlates with poor 
CRC survival, local recurrence and distant metastasis60. Furthermore, high TS 
expression is known to increase the risk of resistance to the widely used 
chemotherapy agent 5-FU since this targets TS61, 62. 
Microsatellite Instability (MSI) 
MSI is the result of a faulty mismatch repair gene (MMR). MMR is responsible 
for genome stability by correcting base-base mismatches during DNA 
replication. Microsatellite instability (MSI) occurs in about 15% of all sporadic 
CRCs. MSI could result in several mutations resulting in over-expression of 
Transforming Growth Factor-β (TGF-β) and Insulin-like Growth Factor (IGF), 
which play a key part in tumour development63, 64. CRC tumours that are MSI-
positive have a better prognosis than those that are Microsatellite Stable (MSS), 
with lower recurrence rates and better overall survival65, 66. 
Vascular Endothelial Growth Factor (VEGF) 
VEGF is the main stimulator of angiogenesis in the body, and is also known to 
be the most important promoter of angiogenesis in CRC. Studies indicate that 
over-expression of VEGF in CRC tumours is linked with poor outcome67, 68. 
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Colorectal Cancer Microenvironment 
Colorectal cancer tumours result from a series of mutations in the genome of 
epithelial cells in the colon and rectum. The resulting alteration in the genome is 
called the “Hallmark of cancer”; inactivating suppressor genes and activating 
oncogenes, leading to69;  
• Rapid, uncontrolled growth due the tumour cell’s independent 
ability to produce growth factors, as well as resisting 
antigrowth signals.  
• Promotion of tissue invasion and metastasis by remodelling of 
the extracellular matrix (ECM).  
• Limitless replication potential 
• Promotion of angiogenesis 
• Avoidance of apoptosis 
An accumulation of mutations and epigenetic alteration in the normal epithelial 
cell paves the way for the transformation of normal colon epithelium, first to 
early adenoma, then to advanced adenoma and finally adenocarcinoma70.  
The Extracellular Matrix 
The extracellular matrix consists of water, proteoglycans, glycoproteins and 
proteins. The structure of the ECM varies between organs. The ECM is not static 
but is constantly being remodelled. Collagen, elastin, fibronectins and laminins 
are the principal proteins of the ECM. Moreover the proteoglycans (PG) supply a 
hydrated gel in the extracellular surroundings providing hydration, buffering and 
stability. Schematic cross sections of the ECM are illustrated in Figure 4. 
The ECM is bioactive and important in adhesion, migration, proliferation and 
survival of the cell, and therefore plays a most important role in the pathobiology 
of cancer71-73. The structure of the ECM surrounding a growing tumour is 
different to normal ECM. The malignant CRC cells as well as surrounding 
stromal cells induce pathways in the ECM leading to the stimulation of invasive 
adenocarcinoma74.  
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In order to invade the ECM and promote tumour invasion and metastasis, the 
tumour cells first release factors that promote attachment to the matrix. Once 
attached, mediators promoting ECM degradation are released providing 
pathways for the tumour cells to migrate across the stroma75.  
Degradation and modification of proteins in the ECM is fundamental to 
colorectal cancer cell invasion. Several types of proteinases are known to be 
involved including serine-, cysteine-, aspartate-, and threonine proteinases as 
well as a family of proteinases called the matrix metalloproteinases (MMPs) that 
form the basis of this thesis76. 
The Peritoneal Surface 
The peritoneum of an adult has an area of about 2 m2. The peritoneal surface is 
divided between parietal peritoneum covering the abdominal wall and visceral 
peritoneum covering the visceral organs. The peritoneum consists of a 
mesothelial cell layer, covering a basement membrane (BM). Beneath the 
basement membrane lies the extracellular matrix of the peritoneum; the 
submesothelial layer77.  
Matrix Metalloproteinases 
Matrix metalloproteinases form a group of enzymes that are capable of 
degrading proteins such as collagens, laminins, fibronectins and proteoglycans in 
the ECM. MMPs are zinc-dependent proteolytic enzymes containing an N-
terminal signal peptide, a pro-domain and a catalytic domain where the zinc ion 
is located. MMPs are either bound to the cell membrane or secreted. Different 
MMPs have different substrates and are divided into collagenases, gelatinases, 
membrane type, stromelysins and matrilysins78, 79.   
MMP regulation is controlled by several mechanisms, including transcription, 
activation and inhibition. Matrix metalloproteinases are at first expressed in an 
inactive pro-form. Already activated MMPs and serine proteinases can activate 
pro-MMP80. Inhibition of active MMP is achieved by Tissue Inhibitors of 
Metalloproteinases (TIMP), and α-2macroglobulin81.  
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MMPs´ Role in Cancer Invasion 
MMPs can be synthesised by tumour cells but the major source of active MMP 
is non-malignant stromal cells such as endothelial and inflammatory cells around 
the tumour. MMP activity and expression is increased in many types of cancer82, 
not only altering the environment around the tumour but also directly affecting 
tumour growth at the cellular level.  
Remodelling of the ECM and changes in cellular adhesion are fundamental to 
tumour invasion and dissemination. Proteolysis of the ECM by MMPs enables 
tumour invasion. Cell to cell adhesion is reduced by cleavage of E-cadherin by 
MMP-3 and MMP-7, facilitating migration83. MMP-1, MMP-8 and MMP-13 
primarily degrade collagens (i.e collagen Types I, II and III) that are key 
components of the intestinal stoma, while the basement membrane primarily 
consists of collagen Type IV. MMP-2, MMP-7 and MMP-9 are matrix 
metalloproteinases that have collagen Type IV as substrate84.  
Cancer cells acquire the capacity to unregulated growth partly by becoming self-
sufficient in growth-factors as well as being resistant to antigrowth signals. TGF-
β is an important factor in the regulation of tumour growth. In normal non-
malignant cells TGF-β act as a tumour-suppressive cytokine but is in the 
malignant context this factor is used by the tumour to achieve invasion and 
metastasis by influencing the surrounding stromal cells. The malignant cell also 
develops resistance to the antiproliferation properties of TGF-β. Several MMPs 
such as MMP-2 and MMP-9 are able to activate TGF-β by converting it from its 
inactive pro-form and thereby have a tumour-promoting effect85, 86. A central 
part of tumour development is tumour angiogenesis. MMPs such as MMP-3, 
MMP-7 and MMP-9 play a major role by regulating the local level of active 
VEGF stimulating angiogenesis and thereby providing the tumour with 
sufficient blood supply and promoting systemic spread87. MMPs are crucial in 
pre-metastatic niche formation through extracellular remodelling. Increased 
MMP concentrations contribute to the recruitment of bone marrow-derived cells, 
and the release of MMPs increases vascular permeability88. Some of the actions 
of MMPs in tumour growth and metastatic spread are shown in Figure 5. 
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Peritoneal Carcinomatosis 
About 5-8% of patients with CRC have developed peritoneal carcinomatosis 
(PC) at the time of diagnosis, making the peritoneal surface the second most 
common site to metastatic disease, following liver metastasis in CRC89, 90.  
Approximately 5% of patients with PC from CRC are treated with cytoreductive 
surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy 
(HIPEC). The median overall survival after this treatment is reported to be about 
32-47 months, compared to systemic chemotherapy alone where the overall 
survival is about 10-17 months16, 91.  
Figure 5. MMPs role in cancer invasion. Invasion of the tumour and cellmigration 
into blood vessels by ECM remodeling and downregulation of cellular adhesion (1). 
Angiogenesis is triggered by VEGF release promoted by MMP-2 and MMP-9 (2). 
Inflammatory cells are recruited to the tumour environment by activating TNF-α (3). 
Metastatic niche formation is facilitated by MMPs (4). Elsevier Inc. With permission. 
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The development of PC comprises five critical steps: 1. the release of cancer 
cells from the primary tumour into the abdominal cavity; 2. the transport of cells 
within the abdominal cavity, primarily by gravity but also gastrointestinal 
movement and the negative pressure caused by movement of the diaphragm; 3. 
thereafter the cancer cells need to adhere to the peritoneal surface where 
inflammatory mediators play a critical role; 4. Invasion of the submesothelial 
tissue then occurs by the degradation of ECM and further adhesion; 5. finally the 
invasion of the stroma beneath the mesothelial layer exposes cancer cells to the 
blood and lymphatic microcirculation92. The process is multifactorial but MMPs 
are thought to play a crucial role in these steps. 
MMPs are key factors in the degradation of surrounding tumour stroma at the 
primary tumour site as well as mediating inflammatory responses, adhesion and 
degradation at the distant site, enabling tumour development on the peritoneal 
surface83, 93-95. It has been shown, both in vitro as well as in animal models, that 
selective MMP-inhibitors reduce PC and prolong survival96. 
Surgery for CRC could cause damage to the primary tumour leading to release of 
free cancer cells that may then adhere to the peritoneal surface. It is known that 
free cancer cells in the peritoneal cavity can lead to PC97-99 Our knowledge of the 
biological interactions in tumour cell adherence to the peritoneal surface is still 
limited, one reason being the absence of a working human experimental model. 
Matrix Metalloproteinases as  
Biomarkers In Colorectal Cancer 
The activity and expression of MMPs is increased in many types of cancer and it 
is proposed that MMP levels measured in systemic blood circulation could be of 
prognostic and diagnostic value in cancer diseases82. Various MMPs, measured 
in blood have been suggested to indicate a possible potential as a diagnostic or 
prognostic marker in CRC100-102.  
Several studies have shown that MMP-9 levels are elevated in the tumour tissue 
and plasma of patients with CRC102, 103 and have suggested that high MMP-9 
levels may be used as a negative prognostic factor in CRC. Furthermore, patients 
with CRC show elevated MMP-9 levels in adjacent tumour-free mucosa and this 
could be used as a predictor for survival104. High MMP-7 concentration in the 
plasma of patients with CRC Stages I-IIB disease has been shown to correlate 
significantly with impaired survival100. MMP-2 in plasma increases with CRC 
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tumour stage and there is a significantly higher concentration in the plasma of 
CRC patients compared to healthy controls102. Furthermore, the serum 
concentration of MMP-8 in patients with colorectal cancer has been found to 
correlate with survival105, 106. Patients with CRC and a high expression of MMP-
1 in tumour-free intestinal mucosa have poorer cancer-specific survival (CCS) 
compared to patients with low MMP-1 expression107. Faecal MMP-9 levels have 
recently gained attention as a promising diagnostic marker for CRC108. 
Measurement of Circulating MMP  
There is a lack of consensus regarding the role of MMPs as prognostic or 
diagnostic markers of CRC when measured in circulating blood. Several studies 
have been performed with varying results. This may be due to the way blood 
samples have been prepared. Some studies on circulating MMPs have shown 
high levels in patients with CRC whereas others have not109-111. Circulating 
MMPs are analysed either in serum or in plasma. Serum is the liquid that 
remains from the portion of the blood when all cells are removed and the blood 
has clotted. In contrast with plasma that is the liquid that remains when clotting 
is prevented with a added anticoagulant. Analysis of serum samples for 
determination of circulating MMPs has previously been criticised112, 113 since 
release of MMPs during the clotting process makes serum samples dependent on 
the time taken to analysis114. A comparison of the levels of certain MMPs in 
serum and plasma has not been fully explored. 
To study cancer-related outcome in larger series, biological samples are usually 
collected and kept frozen until a sufficient number of samples, such as blood and 
tissue, have been collected and can be analysed in batches. The rationale behind 
this is to minimise inter-assay variation and to be more effective in the use of 
laboratory equipment. The stability of cryopreserved biomarkers, including 
MMPs in plasma and tissue samples, has been a matter of debate, and 
inappropriate handling of specimens may lead to degradation of biomarkers in 
cancer tissue115, 116. The long-term cryostability of MMPs in plasma and in 
centrifugal extracts of intestinal mucosa has not been fully investigated117-119.  
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Aim 
The objective of this thesis was to validate methods of measurement and storage 
of biological samples regarding MMP concentration, and to assess the role of 
MMPs as prognostic markers in colorectal cancer. Furthermore, to develop and 
validate an experimental model to investigate CRC cell adhesion in peritoneal 
carcinomatosis 
The specific aims were to: 
• Study I: Determine whether plasma or serum should be used 
when measuring MMPs in peripheral blood. 
 
• Study II: Investigate the long-term stability of MMP-9 levels 
in cryopreserved citrated plasma, and centrifugal extracts of 
tumour tissue and tumour-free intestinal mucosa samples from 
patients with colorectal cancer. 
 
• Study III: Evaluate if MMP-1, 2, 7, 8, and 9 measured in 
plasma could be used as a prognostic indicator for overall 
survival and cancer specific survival in patients treated for 
colorectal cancer. 
 
• Study IV: To develop and validate an experimental model 
using human mesothelial cells and peritoneal tissue samples, 
to investigate CRC cell adhesion in peritoneal carcinomatosis. 
  
Colorectal Cancer -  
MMP as a prognostic marker and a model for peritoneal response 
18 
  
 
Andreas Jonsson 
19 
Methods 
Patients 
Study I 
Men and women 65 years-of-age and living in Kungsbacka municipality, 
Sweden, were asked to participate in a pilot study regarding CRC screening. 
There were 976 persons meeting the criteria of the pilot study. In all, 636 chose 
to participate and informed consent was obtained from all participants. The 
participants were screened for faecal haemoglobin (fHb) and 68 patients who 
were positive were examined by colonoscopy. In 65 of these patients there were 
no signs of CRC or adenoma. Serum and plasma samples from circulating blood 
were also obtained at the time of colonoscopy. Blood samples from 34 males and 
31 women were included in Study I. 
Study II 
Thirty-six samples each of frozen plasma, tumour tissue and tumour-free large 
bowel tissue, respectively, were used in Study II. The samples were obtained 
from 47 patients during CRC surgery at Sahlgrenska University Hospital/Östra, 
Gothenburg, Sweden, between the years of 1999 and 2005. The samples were 
chosen to represent all UICC cancer stages. 
Study III 
A total of 331 patients operated on due to colorectal cancer between 1999 and 
2005 at Sahlgrenska University Hospital/Östra, Gothenburg, Sweden formed the 
cohort of this study. Valid data were available for 272 patients at the end of 
follow-up. 
All surgical resection specimens were sent for a pathological report according to 
the UICC TNM classification system, and staging of the cancer disease was 
made according to the 6th Edition of The American Joint Committee on Cancer. 
Neoadjuvant chemotherapy was not used. Adjuvant chemotherapy was offered 
according to protocol. All participating patients gave informed consent. 
Patients and tumour characteristics were compared to all patients that underwent 
elective surgery for colorectal cancer at Sahlgrenska University Hospital/Östra, 
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Gothenburg, Sweden during the same period of time. The local database at 
Sahlgrenska University Hospital/Östra includes data of all patients that have 
been treated for colorectal cancer since 1999. 
Study IV 
Human mesothelial cells were used in Study IV. Primary cells were harvested 
from three patients undergoing non-septic benign open surgery. These cells were 
cultured to achieve established lines and then frozen in liquid nitrogen prior to 
the experimental set-ups. In the second part of Study IV, peritoneal tissue 
samples were obtained from four patients undergoing elective open surgery for a 
non-septic benign disease. Due to variation in the size of the human peritoneal 
tissue removed, different experimental set-ups were used for each patient. From 
four patients’ tissue samples, seven set-ups were used in the study. 
Data sources 
In Study III, date of death and causes of death were obtained from the Swedish 
National Board of Health and Welfare Cause of Death Register. The register 
contains data for cause of death and covers all deaths in Sweden. The register 
has a coverage of 99.1 % and the underlying cause of death is recorded in 96 % 
of all deaths 120. 
Sample preparation and storage 
Study I  
Venous blood samples were collected in a standardised way. Tubes without clot 
activators were used for serum samples and were stored for 30 minutes at room 
temperature (+20°C) before centrifugation at 10 000 g. The plasma samples were 
collected in citrate tubes and within five minutes centrifuged at 10 000 g at 20°C 
for 10 minutes. After centrifugation the supernatants were collected in small 
aliquots and frozen at -80°C pending analysis in batches. 
Study II 
In Study II, both blood and tissue samples were used. Blood samples were 
collected in citrate tubes after induction of anaesthesia. The tubes were 
centrifuged within five minutes at 10 000 g for 10 minutes at 20°C. Several 
aliquots were taken from each supernatant and were frozen at -80°C pending 
analysis. 
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Surgical biopsies where taken from the tumour and from tumour-free colon, 
approximately 10 cm from the tumour. Tissue samples were about 1 cm2 in size. 
All samples were immediately frozen in liquid nitrogen in the operating theatre 
and further stored in -80°C until tissue extract preparation. In preparation for 
analysis, the samples were thawed, cut into pieces 40 mg in weight and 
homogenised in phosphate-buffered saline (PBS) buffer with 0.01% triton X-100 
using 40 mg tissue per ml buffer. The homogenate was centrifuged at 10 000 g 
for three minutes and the supernatant collected in multiple aliquots and kept 
frozen at -80°C pending analysis. 
Study III  
During induction of anaesthesia, blood samples were collected in citrate tubes in 
a standardised manner and centrifuged at 10 000 g for ten minutes. The 
supernatants where frozen at -80 °C pending analysis. Surgical specimens were 
sent for pathology examination and staging of the tumour was made according to 
6th Edition of The American Joint Committee on Cancer121. 
Study IV 
In Study IV peritoneal tissue, harvested human mesothelial cells and commercial 
available Colo205 tumour cell lines were used. All handling in the culture 
laboratory was performed under aseptic and sterile conditions using a laminar air 
flow (LAF) bench (Holten, Ninolab, Kungsbacka, Sweden). Cultures were 
monitored regularly using inverted phase contrast microscopy and documented 
using the Axiovision system (Carl-Zeiss). 
During surgery, peritoneal tissue samples were removed and placed in culture 
medium E199 (Sigma-Aldrich). The samples were immediately transported to 
the laboratory. The peritoneal samples were cut into 25 x 25 mm squares and 
mounted in our experimental model. The peritoneal squares were mounted 
between two acrylic rings with the mesothelial surface pointing upwards, see 
Figure 6. When the preparations were ready the samples were submerged into a 
cell culture dish where the culture medium was completely changed three times 
a week. 
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Frozen cell lines from human primary mesothelial cells previously harvested 
from the peritoneal fluid of patients undergoing surgery for non-septic benign 
disease. The cells were cultured in a cell incubator at 37°C and sub-cultured 
when confluent cell layers were observed. Growth medium was changed tree 
times a week. 
A commercially available human colon cancer cell line, Colo205 was used. The 
cells were cultured and sub-cultured in a manner similar to the mesothelial cells. 
Cell lines were initiated by thawing the frozen ampoule in a water bath at 37°C. 
The cells where then suspended in culture medium and centrifuged at 260 g for 
10 minutes. The supernatant could then be discarded and the cell pellet 
transferred to a cell culture flask 
Luminex xMAP 
In Studies I and III the MMP measurements in serum and citrated plasma were 
carried out using Luminex xMap technology. Luminex xMAP uses small, 
colour-coded beads that are coated with an antibody designed to capture the 
specific analyte of interest. The sample, containing the desired analyte is then 
introduced in the assay (Figure 7A). A “sandwich” is thereafter created using an 
additional detection antibody aimed at the analyte. A fluorochrome 
(phycoerythrin) is added as substrate and binds to the detection antibody (figure 
7B). The samples are then analysed with the Luminex xMap multi-assay 
technology (Bio-Plex 200, BIO-RAD, Sundbyberg, Sweden). The instrument 
detects each colour code of the beads with one laser and a second laser beam 
Figure 6. The human ex vivo tumour invasion model. Human 
peritoneum is placed between two acrylic rings during sterile 
conditions and placed in a cell culture incubator. The 
peritoneal membrane could then be monitored using inverted 
light microscope. 
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determines the amount of signal from the added fluorochrome from each bead 
(Figure 7C). The level of MMP in the samples was calculated using a five 
parameter logistic (5-PL) standard curve122. Each sample was measured in 
duplicate. 
 
Figure 7A-C. The sample is introduced (A). A sandwich is 
created with a detection antibody (B). The instrument detects 
each color code and measure the amount of signal from the 
added flourochrome (C). R&D Systems, Bio-Techne, 
Minneapolis, USA. With permission.  
Colorectal Cancer -  
MMP as a prognostic marker and a model for peritoneal response 
24 
Levels of MMP-1, MMP-2, MMP-7, MMP-8, MMP-9 and MMP-13 were 
investigated in Studies I and III. Specific kits were purchased for these analyses. 
Their lower detection limit, intra- and interassay coefficients of variability (CV) 
are shown in Table 2. 
Enzyme-linked Immunosorbent Assay (ELISA) 
ELISA technology was used in Study II for the measurement of MMP-9. The 
assay has 96 wells and is performed with the sandwich technique. Each well is 
precoated with the specific antibody that binds to MMP-9 when the sample is 
added. In the second step, the detection antibody is added and forms a sandwich 
complex. The substrate is then added, and after the addition of an acid solution 
to stop further reaction the plate is measured at a wavelength of 450 nm in a 
multi-well plate reader, see Figure 8. The colour intensity is proportional to the 
amount of detected MMP-9 in each sample123. 
Table 2. Detection limits and CVs of investigated MMPs 
Analyte Detection LDL (pg/ml) Intra-Assay CV (%) Inter-Assay CV (%) 
MMP-1 P, M, Ti 0.57 7.8 – 9.0 15.3 – 16.2 
MMP-2 P, M 3.8 7.3 – 9.3 10.0 – 13.3 
MMP-7 P, M, Ti 3.9 5.0 – 9.0 7.7 – 11.5 
MMP-8 P, M, Ti 7.8 5.2 – 7.0 9.6 – 14.3 
MMP-9 P, M, Ti 5.7 3.8 – 5.8 9.3 – 11.7 
MMP-13 P, M, Ti 36.5 4.3 – 5.6 10.7 – 12.6 
Abbrevations: LDL = Lower Detection Limit; CV = Coefficient of Variation;  
MMP = Matrix metalloproteinase; P = Proform; M = Mature; Ti = MMP bound to Tissue Inhibitor 
of Metallproteinases. 
Figure 8. Direct sandwich ELISA Principle. A well is coated with a 
capture antibody, the analyte is added and thereafter a detection 
antibody. The substrate is added and the plate is measured in a 
multiwall-based plate reader. Bio-Rad Laboratories. With 
permission 
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The concentration of MMP-9 from plasma and the centrifuged homogenate was 
measured by absorbance using a standard curve and internal controls with known 
concentrations. The kit has an intra- and interassay CV of 4.9 - 5.5 % and 8.1 - 
9.8 %, respectively, and the lower detection limit is 0.6 ng/mL. Each sample was 
measured in duplicate. 
In vitro and ex vivo Trauma Models 
Tumour Cells Labelling 
In Study IV an in vitro as well as an ex vivo model were developed. Commercial 
available Colo205 cancer cells were used in the model. Before introduction of 
the tumour cells to each model they were labelled with a lipophilic tracer kit 
using fluorescent carbocyanine dye (Vybrant, Molecular Probes, Thermo Fisher 
Scientific, Waltham, MA, USA). This type of labelling is strong and remains 
visible for up to a week, and tumour cells remains fluorescent throughout sub-
cultivation and the technique does not affect cell growth and proliferation. The 
labelling was performed before tumour cell introduction to our trauma model. 
The fluorochrome solution was added to the cell suspension and incubated for 30 
minutes at 37 °C in the cell culture incubator. After centrifugation for 10 minutes 
at 260 g, the cells were resuspended in E199 growth medium. 
Imitating Surgical Trauma in the Mesothelial  
Cell Layer and Human Peritoneal Tissue Model 
A culture plate was used for mesothelial cell cultivation. When a confluent layer 
of cells had developed, surgical trauma was imitated by scraping the monolayer 
with a sterile plastic pipette. The same procedure was performed with the 
peritoneal membrane in the ex vivo peritoneal model. To enable measurement of 
the wounded area, a calibrated size marker with software connected to the 
microscope was used (Axiovision, Carl Zeiss AG, Germany).  
Introduction of Tumour Cells to the Trauma Models 
The Colo205 cells were cultured in culture flasks, detached using trypsin/EDTA 
solution and resuspended in preheated culture medium. The cell pellets were 
produced by centrifugation at 260 g for 10 minutes and discarding the 
supernatant. To produce two different density suspensions, the cells were diluted 
and further resuspended in 5 ml E199 medium as 10 000 cells/mL and 100 000 
cells/mL. The concentrations were verified by cell counting in a 
haemocytometer. The suspensions with low and high cell density were then 
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introduced to the traumatised cultured mesothelial cell layer model and the 
traumatised human peritoneal model respectively. 
Monitoring and Photo Documentation 
Cell cultures and the human peritoneal ex vivo models were monitored using 
inverted microscopy (Axiovision, Carl Zeiss AG, Germany). Photographic 
documentation was carried out at 0, 1, 2, 16, 24, 48, 96 and 192 hours after 
tumour cell introduction. Labelled tumour cells were photo documented using a 
mercury lamp together with a fluorescein isothiocyanate (FITC) and tetramethyl-
rhodamine isothiocyanate (TRITC) filter set. 
Statistics 
The first three papers included in this thesis used statistical calculations. All tests 
were two-sided and p < 0.05 was considered significant. All calculations were 
carried out with IBM SPSS Statistics for Macintosh (Ver. 22.0, IBM Corp, 
Armonk, NY). 
Paper I 
In Paper I levels of MMP-1, MMP-8, MMP-9 were transformed with the natural 
logarithm to achieve normally distributed data and dependent t-test was used to 
compare means between plasma and serum samples concentrations. MMP-2 and 
MMP-7 were not normally distributed, even after transformation. Thus, the 
Wilcoxon signed rank test was used to compare medians. The Spearman rank 
correlation test was used to estimate correlation. 
Paper II 
In Paper II, MMP-9 concentrations were compared before and after 
cryopreservation. The Wilcoxon signed rank test was used to compare MMP-9 
concentrations at baseline and after nine years of storage (plasma group) and at 
baseline and after twelve years of storage (tissue extract group). Correlations 
were estimated using the Spearman rank correlation test. 
To visualise agreement between baseline and cryopreserved values, Bland-
Altman plots were used. An estimated confidence interval of 95% of the mean 
difference of recovery rate was applied124.  
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Paper III 
Receiver operating characteristic (ROC) curves were used to divide MMP 
plasma levels between high and low levels. ROC curves were based on plasma 
MMP levels and data for survival, and the optimal cut-off value was estimated 
and used as a dichotomous variable in further analysis. 
Kaplan-Meier curves were used to illustrate survival over time. Log-Rank tests 
were used to test for level of significance. Cox proportional hazard models were 
used to estimate the prognostic value of plasma MMP expression. Univariate 
analysis of UICC cancer stage, age, tumour site, the use of adjuvant treatment 
and MMP plasma level were executed. Variables with a p-value below 0.16 in 
univariate analysis were used in multivariable analysis125. Variance Inflation 
Factor (VIF) was calculated for each variable included in the multivariate 
analyses to test for multi-collinearity. Hazard ratios (HR) were displayed with a 
95 % confidence interval (CI 95 %). 
As we tested for several different MMPs in Study III there was an underlying 
risk of multiplicity. The more hypotheses tested the higher is the risk of “false” 
significance at the 5 % level. There are several models to correct for the risk of 
multiplicity. An often used procedure is the Bonferroni correction where the 
desired significance level is divided by the number of tested hypotheses. On the 
other hand, by choosing values using the Bonferroni correction or similar, there 
is some risk of missing actual differences. Study III evaluated the possible roles 
of several MMPs as prognostic factors in colorectal cancer, the study was more 
of an explorative nature aimed to find possible biomarkers, and with that 
intention multiplicity correction was not required. However, we did bear the risk 
of multiplicity in mind when interpreting our results and drawing conclusions.  
Ethical Considerations 
Informed consent was obtained from all participating patients. The studies were 
approved by the Ethics Committee at Lund University Hospital, Lund, Sweden 
and Sahlgrenska University Hospital, Gothenburg, Sweden. 
Paper I: 2010-591, Paper II: LO19-99, Paper III: LO19-99 and 424-17, and 
Paper IV: Ö727-03 and Ö728-03 
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Results and Discussion 
I. The Use of Citrated Plasma or  
Serum Samples in the Measurement  
of Systemic MMP Levels 
MMP blood concentrations were measured in 65 patients, 65 years-of-age, with 
no sign of CRC at colonoscopy. Samples were taken as citrated plasma and 
serum. All samples were analysed in duplicate. 
For all MMPs measured (MMP-1, MMP-2, MMP-7, MMP-8 and MMP-9), the 
levels in serum were found to be higher than those in plasma (p < 0.01). The 
concentrations of MMP-13 were found to be under the detection limit of the 
assay in all samples, and were thus not reported. 
MMP-1 was 7.9 times higher in the serum group compared to the citrated plasma 
group (p < 0.01, n = 65), for MMP-2 the levels in serum were found to be 1.2 
times higher (p < 0.01, n = 65). MMP-7 was 1.5 higher in the serum group, 
while MMP-8 and MMP-9 were found to be 4.7 and 5.6 times higher in serum 
compared to citrated plasma. There were no differences in MMP concentrations 
between male and female patients, in both the serum and citrated plasma groups 
(p > 0.05). Medians and interquartile ranges are reported in Table 3. 
Interquartile ranges were all greater in the serum group compared to the plasma, 
indicating a wider distribution. The results are visualised in boxplots according 
to Figures 9A-E.  
Table 3. Medians and interquartile ranges of MMP levels in plasma vs serum 
 Plasma Serum p-value 
MMP-1 ng/ml (IQR) 0.725 (0.921) 5.70 (6.50) < 0.01 
MMP-2 ng/ml (IQR) 288 (216) 340 (252) < 0.01 
MMP-7 ng/ml (IQR) 2.45 (2.31) 3.56 (2.66) < 0.01 
MMP-8 ng/ml (IQR) 1.82 (4.06) 8.47 (13.5) < 0.01 
MMP-9 ng/ml (IQR) 48.2 (64.7) 270 (254) < 0.01 
Abbreviations: IQR = Interquartile range; MMP = Matrix metalloproteinase 
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A. B. 
C. D. 
E. 
Figure 9A-E. MMP in Citrate plasma and 
serum. A significant higher level was found 
in serum in all analyses. MMP-1 in A, 
MMP-2 in B, MMP-7 in C, MMP-8 in D 
and MMP-9 in E. Boxes represents lower 
and upper quartile and median. Whiskers 
represent min and max values. Outliers 
indicated by o. 
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This study involved a large sample size and compared several MMPs in plasma 
and serum. Despite this, the material must be seen as restricted since it 
comprised patients of the same age. Furthermore, the patients could not be 
regarded as a “healthy” group since the only exclusion criterion in the study was 
sign of CRC at colonoscopy. It is known that MMP varies with age, and 
previous studies have reported gender differences126, 127. . The present study did 
not find any significant difference in MMP concentrations between males and 
females in the serum or plasma group. The difference between MMP levels in 
serum and plasma, however, was quite clear, regardless of age or sex. 
Our results concur with previous work on MMP levels in plasma and serum. 
Previous studies have used fewer patients and/or analysed fewer forms of 
MMP128, 129 some showing no significant difference between MMP levels in 
serum and in plasma. However, the results of the present study in this thesis 
were based on a larger sample size113, 130. One study looking at MMP-9 levels in 
plasma and serum of patients with gastric cancer gave different results; the 
authors found a significant difference in plasma MMP-9 levels in patients with 
known gastric cancer compared to healthy controls. However no difference was 
seen when serum MMP-9 levels were compared131.  
In Study I we used citrate as anticoagulant for the plasma samples. EDTA or 
heparin could have been used, but previous studies indicate that citrated plasma 
has less variability and is more stable during prolonged storage before 
centrifugation112, 130.  
In Paper I we report higher concentrations and wider distribution of MMP levels 
in serum compared to corresponding citrated plasma samples. The reason for the 
greater interquartile ranges and overall higher concentrations in serum is not 
fully understood. There might be release of proteases during the clotting process 
in the serum tube that the anticoagulant properties of citrate prevent114. The 
concentrations of several MMPs in serum tubes are known to increase as the 
time between venous sampling and centrifugation is prolonged. This could be 
due to MMPs in platelets, neutrophils and white blood cells being released 
during aggregation132-134. MMP-2 levels, however, are not greatly affected by the 
clotting process, which may explain our results where MMP-2 in serum did not 
differ as much from plasma135.  
Paper 1 concludes that the value of MMP levels measured in serum is limited 
due to greater variability and dependency on the time-to-analysis compared to 
levels analysed in plasma. 
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II. Reliability of Frozen Plasma  
and Tissue Samples When  
Measuring MMP Concentration 
To validate our cryopreservation set-up, 36 samples from each plasma, tumour 
tissue extract and extract from intestinal tumour-free tissue were analysed for 
MMP-9. The samples from plasma were stored for nine years and all tissue 
samples were stored for 12 years. The samples were analysed at baseline i.e. 
within 24 months following surgery. Corresponding aliquots were then analysed 
after cryopreservation.  
MMP-9 in plasma had a baseline median concentration of 9.9 ng/mL. The 
median level after 9 years of cryopreservation was 9.7 ng/mL. This difference is 
not significant according to the Wilcoxon signed rank test (p > 0.05).  
Cryopreservation of tumour-free intestinal tissue extract showed an increase in 
concentration over storage time. MMP-9 at baseline was 7.1 ng/mL and after 
cryopreservation 8.1 ng/mL. When tested with Wilcoxon signed rank test the 
levels were found to differ significantly (p < 0.05).  
The baseline concentration of MMP-9 in the tumour tissue extract samples was 
89.9 ng/mL. After 12 years cryopreservation a significant increase (133.5 
ng/mL) was seen (p < 0.05).  
The Spearman rank correlation test was carried out on all pre- and post-
cryopreservation samples. There was a distinct correlation between the samples 
of all sample types investigated. Spearmans rho as well as medians and ranges 
are reported in Table 4. 
Table 4. Medians, interquartile ranges and Spearman rho pre- and post cryopreservation. 
 BL analysis P analysis p value ρ (p value) 
MMP-9 P ng/mL (IQR) 9.9 (12.2) 9.7 (12.4) 0.13 0.96 (< 0.01) 
MMP-9 HIT ng/mL (IQR) 7.1 (13.4) 8.1 (17.7) < 0.01 0.97 (< 0.01) 
MMP-9 TT ng/mL (IQR) 89.9 (175.4) 133.5 (234.5) < 0.01 0.97 (< 0.01) 
Abbreviations: BL = Baseline; P = Present; MMP = Matrix metalloproteinase; IQR = 
Interquartile range; P = Plasma; HIT = Healthy intestinal tissue; TT = Tumor tissue. 
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Bland-Altman plots (Figures 10A-C) were constructed to visualise the difference 
to mean of each analysis. In the plots the mean value of all pre-cryopreserved 
samples are indicated with a line and all values from each of the 36 samples are 
plotted as the mean of the pre- and post-cryopreserved paired samples (X axis) 
and the difference to the mean of all samples (Y axis). There is a greater spread 
from the mean axis in the tumour-tissue samples and the tumour-free intestinal 
tissue sample, compared to the plasma samples, where no significant difference 
was seen according to the Wilcoxon rank test. 
The cryostability of MMP-9 measured in plasma and tissue extract was 
investigated in Study II. We used our own biobank and standardised sampling 
conditions to imitate a clinical, real-time set-up. MMP levels in plasma remained 
stable over a long period of time in cryopreservation, whilst tissue extracts from 
tumour and adjacent tumour-free intestinal tissue showed increases over time.  
The Arrhenius equation is described in this paper since others have used it for 
calculation of MMP stability. Previous studies on real-time stability as well as 
calculations using the Arrhenius equation have shown MMP to be stable117-119, 
136, whilst Rouy et al found MMP-9 to dramatically decrease during storage115. 
Before our study, however, no one had studied real-time stability of MMP for 
such a long period of time. Rouy et al also used a different approach as they 
compared pooled samples of MMP that had been cryopreserved over different 
periods of time. The study in this thesis used paired samples from each patient. 
In the study presented in this thesis, the ELISA technique was used to determine 
the level of MMP-9. MMP-9 is one of the most important enzymes involved in 
the degradation of ECM, and several studies have used MMP-9 when 
investigating biomarkers in CRC102, 103. 
The recovery of MMP from cryopreserved plasma samples was almost 100 % 
and there was no difference between baseline and final values according to the 
Wilcoxon rank test. Correlation was almost linear. However, an increase in 
MMP was seen in both types of cryopreserved tissue extract; the tumour extracts 
increasing the most. We cannot explain the reasons for this. There is a certain 
risk of cell damage and thereby MMP leakage during the tissue homogenisation 
process. Tumour tissue being more cellular could result in higher concentrations 
due to leakage compared to tumour-free intestinal tissue samples. There is also a 
risk that the paired aliquot taken from the extract contains more or fewer 
damaged cells. This cannot, however, fully explain why the frozen samples 
increase in MMP concentration. Further research is wanted to explain this 
phenomenon.  
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A. 
B. 
C. 
Figure 10A-C. Bland–Altman 
plot showing the difference to 
mean for each analysis. Dots 
that are between upper and 
lower dotted lines represent 
values within the 95% 
confidence interval. A; 
cryopreserved plasma 
samples, B; cryopreserved 
healthy tissue samples and C; 
cryopreserved tumour tissue 
samples. 
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In Paper II we used Spearman correlation analyses, and interestingly there were 
good correlations within all three groups investigated. This highlights the 
limitation of the correlation test, a strong linear relationship does not necessarily 
mean strong agreement between two tested concentrations before and after 
cryopreservation. The Bland-Altman plots reported in the paper visualise 
differences from the mean of each paired sample from the mean of the whole 
group. This gives a good picture of changes in concentration during 
cryopreservation, but it too has its limitations. The calculated 95 % confidence 
interval is a construct by the standard deviation of the analyses. As the CI is 
calculated from the mean difference they become somewhat misleading as the 
mean differs from the zero mark that represents no difference at all. This could, 
however, have been circumvented using a relative difference in the plots, but 
that postulates normally distributed data, which was not the case. The Bland-
Altman plots should thus be seen as a visualisation tool rather than a statistical 
test124.  
In all, 36 samples of plasma and centrifugal extracts from tumour tissue and 
tumour-free intestinal tissue from patients operated for CRC were analysed. The 
baseline concentrations were known from previous research and samples were 
chosen to represent concentrations of MMP-9 in plasma as well as in tissue 
extract at both low and high levels. The samples were also chosen to have a 
relevant case mix at different stages of CRC. In some cases it was not possible to 
analyse the cryopreserved aliquot. To compensate for this the group was 
extended with further samples to achieve 36 paired samples in each group. The 
limitation of this is clear, as it did not keep to the definition of randomised 
sampling. 
A second limitation of the present study is the use of different storage times. Due 
to the need to analyse samples in batches, storage times between sampling point 
and baseline analysis differed. Furthermore the time in storage between pre- and 
post-cryopreservation varied between plasma and tissue extract analysis. 
We conclude that MMP levels in citrated plasma samples stored at -80 °C 
storage remain stable. This is important for retrospective as well as prospective 
research regarding plasma MMP as a biomarker in CRC. It also seems that MMP 
levels in tissue samples increase during long-term cryopreservation.  
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III. Plasma MMP Levels as a  
Prognostic Marker in CRC 
The prognostic value of MMP levels in plasma was evaluated in Study III. A 
cohort of patients operated for CRC between 1999 and 2005 was used. Of a total 
of 331 patients, valid data were available for 272. Patients who received 
preoperative irradiation were excluded as irradiation affects MMP expression137, 
138. 
Patient characteristics are shown in Table 5.  Of a total of 200 patients included 
in the study, 48 patients were treated for rectal cancer and 152 patients were 
treated for colon cancer. Comparison was made with all patients that underwent 
planed surgery for colorectal cancer disease, under the same time period at the 
Sahlgrenska Hospital/Östra, Gothenburg, Sweden, in order to assess the degree 
of representation of our cohort, see Table 5. The median age of patients as well 
as cancer stage distribution was quite similar. There was a difference in the 
distribution of tumour localisation as the study cohort had relatively more 
patients with tumour in the sigmoid and fewer patients with right-sided colon 
cancer. There was equal division of cancers between the colon and rectum but 
there were more patients receiving neoadjuvant radiotherapy in the study cohort.  
Using ROC curves the optimal cut-off value was estimated for each MMP. 
MMP-1 was found to have an area under the curve (AUC) significant larger than 
0.5 and was therefore used in further analysis. The optimal cut-off value was a 
plasma concentration of 336 pg/ml and patients were divided between those with 
a low MMP-1 plasma value (i.e <336 pg/ml) and those with a high MMP-1 
plasma value (>336 pg/ml).  
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Survival analyses were made using Kaplain-Meier curves. A high MMP-1 value 
was associated with poor cancer-specific survival in the total group of patients (p 
< 0.05). Analyses where then made regarding patients with non-disseminated 
colorectal cancer disease (Figure 11A) showing a significant difference in 
survival of patients with high and low plasma MMP-1 levels. In subgroup 
analysis of the Stage III group (Figure 11B) the Kaplain-Meier curve showed 
that a high plasma MMP-1 concentration was associated with poor cancer-
specific 5-year survival. These differences in survival remained when 10-year 
cancer-specific survival was analysed.  
Table 5. Patients characteristics, distribution of UICC stage, tumour localisation 
and the use of neoadjuvant radiotherapy and adjuvant chemotherapy. 
  Study group Total population of 
operated patients  
Median age  (IQR) 72 (65 - 80) 71 (62 - 79) 
Males/Femals (%) 151/121 (55.9/44.1) 667/632 (51.3/48.7) 
UICC Stage 
I (%) 41 (15.1) 188 (14.5) 
II (%) 95 (34.9) 460 (35.5) 
III (%) 99 (36.4) 477 (36.7) 
IV (%) 37 (13.6) 163 (12.5) 
N/A (%) 11 (0.9) 
Total (n) 272 1299 
Tumour localisation: 
Ascending colon (%) 66 (24.3) 410 (31.5) 
Transverse colon (%) 8 (2.9) 27 (2.1) 
Descending colon (%) 16 (5.9) 49 (3.8) 
Sigmoid colon (%) 62 (22.8) 242 (18.6) 
Total colon (%) 152 (55.9) 728 (56.0) 
Rectum (%) 120 (44.1) 571 (44.0) 
Adjuvant CMT 
Yes (%) 57 (21.0) 320 (24.6) 
No (%) 215 (79.0) 979 (75.4) 
Neoadjuvant RT, Rectal Cancer 
Yes (%) 72 (60.0) 253 (44.3) 
No (%) 48 (40.0) 318 (55.7) 
Abbrevations: IQR = Interquartile range; CMT = Chemotherapy; RT = Radiotherapy 
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A. 
B. 
Figure 11A-B.  Cancer specific 5-year survival in patients with 
colorectal cancer, UICC stage I-III (A) and cancer specific 5-
year survival in patients with stage III colorectal cancer (B). 
Divided in patients with high (>336 pg/ml) and low (<336 
pg/ml) MMP-1 plasma concentration (p < 0.05)  
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Using univariate Cox analysis, covariates were evaluated and used in multi-
variable analysis for Hazard Ratio estimations. In patients with metastatic 
disease there was no association between MMP-1 level and survival, and neither 
age nor tumour localisation had an impact on survival. In patients with Stages I-
III colorectal cancer, univariate analysis demonstrated that age, stage and a high 
MMP-1 plasma level were significant for 5-year cancer-specific survival. In 
multivariate analyses age and cancer stage were the only variables with a 
significant impact on survival. In analyses of overall 5-year survival in the 
Stages I-III cancer group, a high MMP-1 value, cancer stage and age all had a p-
value below 0.16 in univariate analysis and were used in multivariate analyses 
where high MMP-1 level did not have an impact on survival 
Patients with Stage III colorectal cancer (n = 67) were analysed in univariate 
analysis. Variables with a p-value below 0.16 were used in multivariate Cox 
analysis where a high level of MMP-1 in plasma was found to be a negative 
predictor of 5-year cancer-specific survival (31 events, HR 2.99, CI 1.15 - 5.87). 
In multivariate analysis of overall 5-year survival, only treatment with adjuvant 
chemotherapy was found to be of prognostic value. There were 54 patients with 
Stage III colon cancer. In this group a high MMP-1 value was a negative 
prognostic factor in multivariable analysis for 5-year cancer-specific survival (26 
events, HR 2.7 CI 1.05 - 6.82). 
The prognostic value of MMP-1 concentration in plasma was also evaluated by 
multivariate analysis for 10-year cancer-specific survival in patients with Stage 
III colorectal cancer (37 events, HR 2.91 CI 1.33 - 6.38). A high MMP-1 value 
was a negative prognostic factor of 10-year cancer-specific survival for patients 
with Stage III colon cancer (31 events, HR 2.55 CI 1.07 – 6.10).   
In paper III the prognostic value of MMP measured in circulating plasma was 
evaluated and MMP-1 was found to have an impact of cancer specific survival. 
MMP concentrations in systemic blood have earlier been studied regarded 
colorectal cancer survival; this is shown in MMP-2, MMP-7, MMP-8 and MMP-
9 where concentrations were measured in serum101, 105, 106, 139, 140. However, paper 
III studied levels of MMP in plasma samples that are known to be more stable 
than, serum141. 
The findings in paper III is of importance as our prognostic models for survival 
after colorectal cancer surgery are somewhat insufficient. Advanced stage II 
colorectal cancers as well as stage III are of special interest as this are the groups 
of patients receiving adjuvant chemotherapy follow surgery. Unfortunately, just 
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about 15 % of all patients receiving adjuvant chemotherapy avoid recurrence due 
to the chemotherapy treatment44, 142, 143. The prognostic value of MMP-1 in 
plasma for patients with Stages II-III colorectal cancer undergoing surgery could 
be of importance as a supplement to TNM staging when identifying patients for 
adjuvant treatment. As seen in Figures 11A-B, patients with a high MMP-1 value 
had a poor cancer-specific survival and it is shown that the largest difference in 
outcome for patients with high and low values are seen within the first three 
years. This is in concordance with previous findings where the majority of 
colorectal cancer recurrences have been reported to appear in the first three years 
after surgery, highlighting the need for improved prognostic models for survival 
in colorectal cancer disease144. In a further analysis (data not reported) we found 
that MMP-1 levels in plasma had a significant prognostic impact on survival in 
patients with Stage II – III colorectal cancer who did not receive adjuvant 
chemotherapy, see Figure 12. In multivariate analysis together with age and 
cancer stage a high MMP-1 level was a predictor of cancer-specific survival (35 
events, HR 2.3 CI 1.09 – 5.01). These findings might be of importance regarding 
further improvement in the criteria required when deciding on adjuvant 
chemotherapy. 
Figure 12.  Cancer specific 5-year survival in patients with 
colorectal cancer, UICC stage II-III without adjuvant 
chemotherapy. Divided in patients with high (>336 pg/ml) and 
low (<336 pg/ml) MMP-1 plasma concentration (p < 0.05)  
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In paper III there were some limitations; the nature of long-term follow-up 
studies postulate that treatment protocol, surgical and pathological technique 
might have changed during the time period. There were relatively few patients 
with rectal cancer disease as patients receiving neoadjuvant radiotherapy were 
excluded.  
We conclude that the findings reported in Paper III could support the use of 
MMP-1 plasma levels as a prognostic tool in patients treated for colorectal 
cancer. As well it might be of importance in the selection of patients that ought 
to receive adjuvant chemotherapy following colorectal cancer surgery. More 
studies are to be conducted to verify the results.  
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IV. The Use of ex Vivo and in Vitro Models  
to Study the Role of Surgical Trauma in  
Peritoneal Carcinomatosis 
In paper IV a model to understanding the role of surgical trauma for cancer 
spread to the peritoneal surface was developed. The study was experimental. 
The cell cultures of harvested mesothelial cells as well as Colo205 tumour cells 
were not affected by isolation, subcultivation or storage in liquid nitrogen. The 
ex vivo model of human peritoneum was kept without contamination for more 
than 14 days. Migrating fibroblasts were seen to be present indicating viability 
of the peritoneal cells after 8 days culture. 
Following localised trauma to the mesothelial cell layer we observed that added 
Colo205 cancer cells adhered to the traumatised area to a greater extent than to 
the non-traumatised area. The same observation was made regardless of cell 
density of the Colo205 suspension added. Time-lapse photographs of adherence 
of tumour cells to the mesothelial layer are shown in Figure 13. 
Figure 13.  Mesothelial cell layer trauma model with tumour cells added. Edges of the 
damaged area indicated by ----. A greater number of tumour cells were attached to the 
damaged mesothelial area (h) than to the undamaged (d), after 96 hours in culture.  
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A tendency of tumour cells adhesion in clusters to the edge of the traumatized 
area was also seen in the peritoneal ex vivo model. As for the mesothelial cell 
model the same tendency was seen regardless of the cell density of the Colo205 
suspension added, Figures 14a-f. 
 
 
Paper IV may be seen as a form of validation of our constructed ex vivo and in 
vitro models. Due to the methods used in this experimental approach, no 
quantitative conclusions could be drawn. 
This is not the first experimental model for studying the peritoneum ex vivo. 
Previous studies have been carried out in animal models using rats145, 146 and 
mice147, 148. Research on human ex vivo peritoneal models has also been carried 
out, though the viability of that model was restricted to 72 hours compared to the 
model used in this thesis where viability was confirmed after 8 days149. 
In this paper we report that artificial surgical trauma appears to facilitate colon 
cancer cell adherence to the peritoneal surface. The reasons for this are not fully 
understood. Previous studies have suggested that surgical trauma induces 
mediators and proteases, including MMP, that facilitate adherence and 
metastasis to the peritoneal surface97, 149, 150.  
Figure 14. Images of added tumour cells in the ex vivo human peritoneal membrane 
model. By combining the images from light microscopy of the peritoneal ex vivo model (a) 
with the labelled tumour cells (b), a summary image of labelled tumour cells could be 
seen on the peritoneal surface (c). Low cell density numbers (a-c) compared to high 
numbers (d-f). Tumour cells adhere to the edges in a similar manner to that seen with the 
monolayer of mesothelial cells.  
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In conclusion, in our models mesothelial cell and peritoneal tissue were kept 
alive and could be under regular monitoring for a long period of time. Photo 
documentation revealed a tendency for cancer cells to adhere in clusters to the 
edges of the mimicked trauma. 
Since the publication of this study, our group has proceeded by investigating the 
role of MMPs in peritoneal carcinomatosis originating from CRC. Using 
immune-histochemistry. Levels of MMP-1, MMP-2 and TIMP-1 were evaluated 
in tumour-free peritoneal tissue and tumour invaded peritoneal tissue from 
patients undergoing cytoreductive surgery. MMP-2 and TIMP-1 were mostly 
seen in tumour-invaded areas but were not found in tumour free peritoneum. On 
the other hand, MMP-1 was expressed in tumour-free areas and in the invasion 
zone, in proximity to the tumour, but not in the peritoneal areas invaded by 
tumour95. 
These models will be used to further investigate how colorectal cancer cells 
adhere and metastasise at the peritoneal surface They might also be useful in 
research investigating novel intra-abdominal cancer treatments.  
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Conclusions 
• Levels of MMPs in systemic blood should be measured in 
plasma. 
 
• Levels of MMPs in plasma remain stable even though the 
samples have been stored for a long time at -80°C.  
 
• Levels of MMPs in cryopreserved homogenised tissue extract 
from tumour and tumour-free intestinal tissue are not as 
reliable as in plasma. 
 
• MMP-1 levels in the plasma of patients undergoing colorectal 
cancer surgery could have prognostic value regarding cancer-
specific survival 
 
• The ex vivo human peritoneal model as well as the in vitro 
human mesothelial cell model may be used to study colorectal 
cancer cell invasion and intraperitoneal spread. 
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Future perspectives 
This thesis focuses on colorectal cancer and the microenvironment around CRC 
tumours. The goal has been to validate the methodology of blood sample 
handling and of MMP measurement, in order to further investigate MMPs role 
as a prognostic marker in CRC. Our experimental models using peritoneal tissue 
and mesothelial cell culture were used to gain further knowledge in the 
methodology of ex vivo and in vitro studies for future research into the 
intraperitoneal spread of CRC and the role of MMPs in this process. 
The results presented in this thesis imply that levels of MMP-1 in plasma, given 
that the samples investigated are handled and stored correctly, may have 
prognostic value regarding survival of patients with colorectal cancer. Accurate 
prognosis is of great importance in the selection of patients who are likely to 
benefit from adjuvant treatment following surgery. There are a large number of 
patients with CRC Stage II and Stage III disease where the TNM status system 
fails to help in the selection of patients likely to benefit from adjuvant treatment. 
The use of MMP-1 as a prognostic marker could play an important role in our 
efforts to improve selection of candidates for adjuvant treatment and to optimise 
follow-up programmes after colorectal cancer surgery. Postoperative follow-up 
is time-consuming and expensive and the benefit of intense follow-up program-
mes on survival have been questioned151.  
There are several ongoing studies aimed to evaluate whether neoadjuvant 
treatment has a place in the treatment of patients with advanced Stage II and 
Stage III colon cancer. In our cohort of patients with colorectal cancer (data not 
reported), elevated levels of MMP-2 and MMP-9 were significantly higher in 
patients with Stage III disease. We have determined optimal cut-off levels for 
MMP-2 and MMP-9 providing sensitivity and specificity for lymph node 
involvement of 70.4 % and 61.1 % respectively. These figures are comparable 
with the accuracy of computed tomography in finding Stage III disease 
preoperatively, and MMPs may have a future role as biomarkers when 
stratifying patients with advanced colon cancer for neoadjuvant chemotherapy. 
Our ex vivo model is now validated as the harvested peritoneal layer could be 
kept alive for long periods of time. The adhesion of Colo205 cells in clusters 
along the edges of trauma created in our model suggests that the surgical trauma 
itself might have an impact on intraperitoneal spread after CRC surgery. Our 
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model can be used as a tool in further investigation of the role of the surgical 
trauma in carcinomatosis. It can have other uses as well such as the study of the 
biology involved in tumour adhesion and invasion, following changes in various 
mediators and enzymes. Peritoneal tissue already invaded by peritoneal 
carcinomatosis could be used as a model to develop novel medical treatment for 
PC. HIPEC is gaining increasing interest as an alternative for patients with high 
risk for peritoneal recurrence due to colorectal cancer. Even here our model 
might have an important role in our efforts to understand the underlying biology 
of colorectal cancer spread to the peritoneal surface, especially since recent 
studies have reported difficulty in stratifying patients who stand to gain from 
prophylactic HIPEC treatment152.  Tumour- associated macrophages (TAM) are 
thought to play an important role in colorectal cancer invasion, and it has been 
suggested that TAM can interact with cancer stem cells153. Our ex vivo model is 
a great tool to further investigate the role of TAM in colorectal cancer disease 
and our group are planning further studies in this field. 
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